• LAST PRICE
    0.0159
  • TODAY'S CHANGE (%)
    Trending Up0.0019 (13.5714%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0122 / 0.0140
  • Day Range
    Low 0.0122
    High 0.0159
  • 52 Week Range
    Low 0.0085
    High 0.0980
  • Volume
    10,208
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.014
TimeVolumeCNBX
09:48 ET1670.0122
10:03 ET90010.01479
03:34 ET1000.01405
03:48 ET3000.01479
03:50 ET5000.0159
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCNBX
CNBX Pharmaceuticals Inc
494.7K
0.0x
---
United StatesMPHMF
Callitas Health Inc
3.3K
0.0x
---
United StatesIHTI
Integrative Health Technologies Inc
40.0
0.0x
---
United StatesHESG
Health Sciences Group Inc
18.7K
0.0x
---
United StatesMBCI
MabCure Inc
780.0
0.0x
---
United StatesMRPI
Mera Pharmaceuticals Inc
560.0
0.0x
---
As of 2024-03-29

Company Information

CNBX Pharmaceuticals Inc. is a clinical-stage company specializing in the discovery, development and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. The Company's lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS). Its anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) is RCC-33, a therapy being developed primarily in two settings: one to reduce tumor cell activity in CRC patients as a standalone in neoadjuvant treatment or window of opportunity at the time after colonoscopy, prior to cancer staging, and another for patients with refractory to therapy and adjuvant to surgery also at the time after colonoscopy. The Company indents to initiate Phase I/II clinical trials for both candidates: Cannabics SR and RCC-33.

Contact Information

Headquarters
#3 Bethesda Metro Center, Suite 700BETHESDA, MD, United States 20814
Phone
877-424-2429
Fax
---

Executives

Executive Chairman of the Board
Gabriel Yariv
Chief Executive Officer, Director
Eyal Barad
Chief Financial Officer
Uri Ben-Or
Chief Technology Officer
Sanja Goldberg

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$494.7K
Revenue (TTM)
$499.6K
Shares Outstanding
31.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.86
EPS
$-1.38
Book Value
$-0.09
P/E Ratio
0.0x
Price/Sales (TTM)
1.0
Price/Cash Flow (TTM)
---
Operating Margin
-151.42%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.